NEW YORK (TheStreet) -- GlaxoSmithKline
(GSK - Get Report) shares are climbing, up 0.5% to $48.91 on Thursday, following reports in the Guardian that the National Institute of Allergy and Infectious Diseases will be holding a press conference today to announce that an Ebola vaccine developed by the drug manufacturer will begin human trials in the U.K. in the coming weeks.
GlaxoSmithKline will be working with the World Health Organization to distribute the vaccine to help combat an Ebola virus outbreak in West Africa if the trials are successful.
Must Read: 50 Stocks Hedge Funds Love
TheStreet Ratings team rates GLAXOSMITHKLINE PLC as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:"We rate GLAXOSMITHKLINE PLC (GSK) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income." Highlights from the analysis by TheStreet Ratings Team goes as follows:
- You can view the full analysis from the report here: GSK Ratings Report
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.